RT Journal Article
SR Electronic
T1 Clinical assessment and validation of a rapid and sensitive SARS-CoV-2 test using reverse-transcription loop-mediated isothermal amplification
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.12.20095638
DO 10.1101/2020.05.12.20095638
A1 Anahtar, Melis N.
A1 McGrath, Graham E.G.
A1 Rabe, Brian A.
A1 Tanner, Nathan A.
A1 White, Benjamin A.
A1 Lennerz, Jochen K.M.
A1 Branda, John A.
A1 Cepko, Constance L.
A1 Rosenberg, Eric S.
YR 2020
UL http://medrxiv.org/content/early/2020/05/18/2020.05.12.20095638.abstract
AB Amid the enduring COVID-19 pandemic, there is an urgent need for expanded access to rapid and sensitive SARS-CoV-2 testing worldwide. Here we present a simple clinical workflow that uses a sensitive and highly specific colorimetric reverse-transcription loop-mediated isothermal amplification (RT-LAMP) to detect SARS-CoV-2 and takes forty minutes from sample collection to result. This test requires no specialized equipment and costs a few dollars per sample. Nasopharyngeal samples collected in saline were added either directly (unprocessed) to RT-LAMP reactions or first inactivated by a combined chemical and heat treatment step to inhibit RNases and lyse virions and human cells. The specimens were then amplified with two SARS-CoV-2-specific primer sets and an internal specimen control; the resulting color change was visually interpreted. While direct addition of unprocessed specimens to RT-LAMP reactions could reliably detect samples with abundant SARS-CoV-2, the assay sensitivity markedly increased after the addition of an inactivation step. In 62 clinical samples with a wide range of SARS-CoV-2 nucleic acid concentrations, the assay had 87.5% sensitivity and 100% specificity with a limit of detection at least 25 copies/μL, making it an ideal test to rule in infection. To increase sensitivity, samples that tested negative for SARS-CoV-2 by direct sample addition could be reflexed to a purification step, to increase the effective per-reaction sample input volume. In 40 purified samples, the assay yielded a 90% sensitivity and 100% specificity, with a limit of detection comparable to commercially available real-time PCR-based diagnostics that have received Emergency Use Authorization (EUA) from the FDA. This test for SARS-CoV-2 can be performed in a range of settings for a fraction of the price of other available tests, with limited equipment, and without relying on over-burdened supply chains to increase overall testing capacity.Competing Interest StatementCompeting interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: M.N.A is a co-founder and holds equity interest in Day Zero Diagnostics, outside of submitted work. N.A.T. is on multiple patents related to pH-based amplification detection and DNA polymerases. J.A.B. reports grants from Zeus Scientific, grants from bioMerieux, grants from Immunetics, personal fees from T2 Biosystems, personal fees from DiaSorin, personal fees from Roche Diagnostics, grants from Bay Area Lyme Foundation, grants from Lyme Disease Biobank Foundation, outside the submitted work. Harvard University has filed patent applications regarding this technology on behalf of the inventors. Harvard believes strongly that while intellectual property rights serve to incentivize creation of new products, such rights should not become a barrier to addressing urgent and essential health-related needs. To address the global COVID-19 pandemic, Harvard is implementing technology transfer strategies to allow for rapid utilization of available technologies that may be useful for preventing, diagnosing and treating COVID-19 infection. More information can be found at otd.harvard.edu.Funding StatementB.A.R. and C.L.C. are supported by the Howard Hughes Medical Institute. N.A.T. is an employee of New England Biolabs, manufacturer of enzymes and reagent described in this manuscriptAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials.